LivaNova (LIVN) is back on investors’ radar after recent share price moves aligned with solid reported figures, including revenue of $1,433.456 million and net income of $107.145 million, prompting a closer look at its valuation.

LivaNova’s share price has climbed 6.6% over the past month and 26.23% over the past 90 days, while its 1 year total shareholder return of 72.49% contrasts with a 5 year total shareholder return that is slightly down. Recent moves suggest investors are reassessing the company’s risk and growth profile in light of its current earnings and revenue.

If you are weighing what else might fit alongside LivaNova in your portfolio, this is a good moment to scan for opportunities in healthcare and neurology related AI using the 40 healthcare AI stocks

With LivaNova trading near analysts’ price targets but showing an indicated intrinsic discount, the key question is whether recent strength leaves limited upside or if the stock still reflects less than its potential future growth.

Most Popular Narrative: 2.6% Undervalued

The most followed narrative currently places LivaNova’s fair value at $80.60, only slightly above the last close of $78.50. This frames the stock as modestly undervalued on a discounted cash flow basis.

The analysts have a consensus price target of $80.6 for LivaNova based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $95.0, and the most bearish reporting a price target of just $67.0.

Want to understand why this narrative sees room above today’s price? The core story combines firm revenue growth, rising margins, and a future earnings multiple that assumes meaningful scaling ahead.

Result: Fair Value of $80.60 (UNDERVALUED)

However, investors also need to weigh that higher healthcare cost pressure or tighter reimbursement decisions, along with increased competition in cardiopulmonary devices, could challenge this LivaNova narrative.

Another View: What LivaNova’s P/E Is Telling You

While the SWS DCF model points to LivaNova trading below estimated future cash flow value, the earnings multiple paints a less comfortable picture. At a P/E of 40.2x, compared with the US Medical Equipment industry on 24.4x and a fair ratio of 26.9x, the stock carries clear valuation risk if expectations cool.

Next Steps

If this LivaNova story sounds promising, do not just rely on headline metrics. Dig into the details yourself and see what stands out in the 3 key rewards.

Looking for more investment ideas beyond LivaNova?

Do not stop your research with LivaNova. Broaden your watchlist by scanning focused stock ideas that match different risk levels, income needs, and balance sheet strength.

• Target potential mispricing by reviewing companies flagged in the 45 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies in the 8 dividend fortresses.
• Dial down risk while staying invested by checking stocks in the 66 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.